Highlights

  • Clarity Pharmaceuticals secured acceptance of three SAR-bisPSMA abstracts for the European Association of Nuclear Medicine Annual Congress in October 2026, including a top-rated oral presentation.
  • The company’s Phase III AMPLIFY diagnostic trial completed recruitment with 232 participants, while the CLARIFY Phase III study continues towards its target enrolment.
  • The March 2026 quarterly report showed A$197.8 million in cash, with operating outflows of A$25.5 million and an estimated funding runway of around eight quarters.
  • Commercial-scale copper-64 supply arrangements have been secured with Theragenics and Nucleus RadioPharma to support potential future demand.
  • Clarity Pharmaceuticals shares traded at A$2.12, declining 4.93% (-A$0.11) during the session as investors monitored clinical progress and regulatory milestones.

Clarity Pharmaceuticals Ltd (ASX:CU6) is approaching a critical stage in its development journey as its copper-based theranostics platform moves closer to major clinical and regulatory milestones.

The company’s upcoming scientific presentations, advanced clinical trials and manufacturing partnerships strengthen its long-term development pathway. However, the key investment question remains whether clinical data can translate into regulatory approval and commercial adoption.

EANM Presentation Provides External Visibility

Clarity announced that three abstracts from its SAR-bisPSMA program were accepted for the European Association of Nuclear Medicine (EANM) Annual Congress in Vienna, scheduled for October 2026.

The most significant presentation relates to the Co-PSMA trial, an investigator-initiated Phase II study comparing Clarity’s copper-64 SAR-bisPSMA imaging agent against the established 68Ga-PSMA-11 imaging method.

The trial involved 50 men with biochemical recurrence of prostate cancer.

Previously reported results showed:

• Average lesions detected per patient of 1.26 with 64Cu-SAR-bisPSMA compared with 0.48 using 68Ga-PSMA-11.

• Positive scan rates of 78% compared with 36%.

The results provide supportive evidence for Clarity’s imaging platform, although the company’s future commercial success depends primarily on larger registrational trials and regulatory outcomes.

Phase III Trials Remain the Core Value Driver

Clarity’s most important upcoming milestones remain its two Phase III prostate imaging trials.

The AMPLIFY trial completed recruitment in March 2026 with 232 participants.

The study is designed to assess the diagnostic performance of SAR-bisPSMA in men with biochemical recurrence of prostate cancer.

The CLARIFY Phase III trial is evaluating SAR-bisPSMA in patients with high-risk prostate cancer before radical prostatectomy.

The trial is designed to measure sensitivity and specificity for detecting cancer in pelvic lymph nodes.

Clarity expects these studies to support a potential United States regulatory submission, although the company has not disclosed a specific filing timeline.

Copper Theranostics Platform Targets Imaging and Treatment

Clarity’s technology is based on copper theranostics, combining diagnostic imaging and targeted therapy approaches.

The company uses its SAR technology platform to bind copper isotopes to targeting molecules.

The approach focuses on two copper isotopes:

• Copper-64 for diagnostic imaging.

• Copper-67 for targeted therapeutic applications.

The company believes the matched chemistry between imaging and therapy isotopes could support a personalised treatment pathway, where patients are first identified through imaging before receiving targeted therapy.

The platform is being developed primarily around prostate cancer, with additional programs targeting neuroendocrine tumours and other cancers.

Manufacturing Partnerships Support Commercial Preparation

Clarity has invested in supply chain preparation ahead of potential commercialisation.

The company has secured manufacturing arrangements with:

• Nucleus RadioPharma for commercial-scale copper-64 production.

• Theragenics for copper-64 isotope supply.

These agreements are intended to support future clinical and commercial requirements if products receive regulatory approval.

For radiopharmaceutical companies, manufacturing and distribution infrastructure can be a major commercial challenge because radioactive products require specialised production and logistics capabilities.

Establishing supply arrangements early may reduce future launch barriers.

Financial Position Supports Clinical Development

Clarity remains a pre-revenue biotechnology company focused on clinical development.

For the half year ended 31 December 2025:

• Revenue remained limited.

• Net loss was A$55.7 million.

• Research and development expenditure reached A$50.5 million.

During the March 2026 quarter, operating cash outflows were A$25.5 million, while cash stood at A$197.8 million at quarter end.

The company estimated its funding runway at approximately eight quarters.

Clarity also received a A$9.76 million refundable research and development tax offset in May 2026, supporting its funding position.

Why the Development Matters

The EANM presentations provide increased visibility among the medical community, but the major value driver remains clinical validation.

The Co-PSMA data demonstrates the potential of the technology, but registrational approval requires successful outcomes from larger Phase III studies.

The commercial opportunity is significant because prostate cancer imaging represents an established market with existing clinical demand.

However, Clarity must demonstrate that its technology provides meaningful advantages over currently available PSMA imaging options.

Growth Catalysts to Watch

Potential catalysts for Clarity Pharmaceuticals include:

• AMPLIFY Phase III trial results.

• Completion of CLARIFY recruitment and trial progress updates.

• Regulatory pathway clarification for United States submission.

• Further SECuRE therapeutic data using copper-67 SAR-bisPSMA.

• Progress on the Phase III 64Cu-SARTATE neuroendocrine tumour program.

Risks and Challenges

Clinical trial outcomes remain the largest risk for Clarity.

Although earlier studies have produced encouraging results, Phase III trials determine whether diagnostic performance meets regulatory requirements.

The company also faces commercial adoption challenges.

Existing PSMA imaging technologies are already established, and healthcare providers may require evidence of meaningful clinical advantages before changing workflows.

Funding remains another consideration. While Clarity has a significant cash balance, continued development of multiple clinical programs will require ongoing investment.

Manufacturing partnerships also introduce execution risk, as commercial-scale radiopharmaceutical supply requires reliable production and distribution systems.

What Investors Should Watch Next

The next stage of Clarity’s development will focus on clinical data and regulatory preparation.

Key areas to monitor include:

• AMPLIFY trial results and timing.

• CLARIFY recruitment completion.

• Cash balance and quarterly expenditure trends.

• United States regulatory submission plans.

• Progress of commercial manufacturing capability.

Conclusion

Clarity Pharmaceuticals has advanced several important components of its copper theranostics strategy, including near-complete Phase III trials, scientific recognition through EANM presentations and commercial supply agreements.

The company now approaches a decisive period where clinical outcomes will determine whether its technology can move towards regulatory approval and commercialisation.

With shares trading at A$2.12, down 4.93% (-A$0.11), investors are focused on whether Clarity’s clinical progress can translate into a successful product launch pathway.